Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Passive protection of dogs against clinical disease due to Canine parvovirus-2 by specific antibody from chicken egg yolk

Posted by on in 2006
  • Font size: Larger Smaller
  • Hits: 1662
  • Print

 Sa Van Nguyen, Kouji Umeda, Hideaki Yokoyama, Yukinobu Tohya, and Yoshikatsu Kodama

Can J Vet Res. 2006 January; 70(1): 62-64.

Copyright and/or publishing rights held by the Canadian Veterinary Medical Association Immunology Research Institute, GHEN Corporation, 839-1 Sano, Gifu City, 501-1101, Japan (Nguyen, Umeda, Yokoyama, Kodama); Department of Veterinary Microbiology, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan (Tohya).

Corresponding author.
Address all correspondence and reprint requests to Dr. Sa Van Nguyen;
telephone: (81) 58 235 7303; fax: (81) 58 235 7505;
Received October 4, 2004; Accepted April 19, 2005.

The protective effect of immunoglobulins derived from chicken egg yolk (IgY) against infection by Canine parvovirus 2 (CPV-2) was evaluated in 10 beagle dogs orally challenged with a strain of the virus.

The 2-mo-old dogs were divided into 3 groups and treated with powders containing CPV-2 IgY or normal egg yolk for 7 d after the challenge. The 4 dogs receiving normal egg yolk (control group) demonstrated mild symptoms typical of CPV-2 infection, such as vomiting, diarrhea, and weight loss. No symptoms were observed by 16 d after challenge in the 3 dogs receiving 2 g of IgY powder. Of the 3 dogs receiving 0.5 g of IgY powder, 2 had clinical CPV-2 disease; however, the manifestations were less severe than in the control group. Furthermore, the IgY-treated groups had significantly greater weight gain and shorter duration of virus shedding than the control group.

These results indicate that IgY is useful in protecting dogs from CPV-2-induced clinical disease.

Last modified on